Company intelligence / Profile preview

Probisearch

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Probisearch has developed proprietary probiotic strains, including Ligilactobacillus salivarius PS11610, which have shown positive effects on modulating the microbiome in both human infertility cases and pediatric neurodevelopmental disorders. Clinical studies indicate improved outcomes in targeted populations, such as increased pregnancy success rates for couples undergoing assisted reproduction when treated with their probiotic strain.

Therapeutic areas: Infectious DiseasesNeurologyWomen's Health
Modalities: Live biotherapeutic product therapyMicrobial therapyProbiotic
Industry: Biotech

Drug pipeline

4 assets

Bifidobacterium longum subsp. infantis R0033

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Probisearch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probisearch.

Explore the full profile